![Paula Soteropoulos](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Paula Soteropoulos
Directeur/Membre du Conseil chez
RALLYBIO CORPORATION
Fortune : 43 163 $ au 31/05/2026
Profil
Paula Soteropoulos is Chairman at Ensoma, Inc. since 2024.
Holds director roles at JFYNetworks, Inc., Rallybio LLC since 2020, Dianthus Therapeutics OpCo, Inc., Rallybio Corp.
as Lead Independent Director since 2020, Dianthus Therapeutics, Inc. since 2023, Kyowa Kirin, Inc. since 2021, and serves as Venture Advisor at 5AM Venture Management LLC since 2020.
Formerly Chief Executive Officer & Director at Akcea Therapeutics, Inc. from 2018 to 2019.
Independent Non-Executive Director at uniQure NV from 2016 to 2024.
Vice President & GM-Cardiovascular at Genzyme Corp.
from 1992 to 2013.
Senior VP & GM-Cardiometabolic Business at Moderna, Inc. from 2013 to 2014.
Educated at Tufts University with undergraduate and graduate degrees.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
RALLYBIO CORPORATION 0,06% | 19/12/2025 | 2 985 ( 0,06% ) | 43 163 $ | 31/05/2026 |
Postes actifs de Paula Soteropoulos
| Sociétés | Poste | Début |
|---|---|---|
| RALLYBIO CORPORATION | Directeur/Membre du Conseil | 01/10/2020 |
| DIANTHUS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 11/09/2023 |
JFYNetworks, Inc
 JFYNetworks, Inc Services to the Health IndustryHealth Services Operates as nonprofit organization that provides young people to build skills for college and careers | Directeur/Membre du Conseil | - |
Rallybio LLC
 Rallybio LLC Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotech company that delivers groundbreaking therapies | Directeur/Membre du Conseil | 02/11/2020 |
Dianthus Therapeutics, Inc. (Massachusetts)
 Dianthus Therapeutics, Inc. (Massachusetts) BiotechnologyHealth Technology Develops therapies for severe autoimmune diseases | Directeur/Membre du Conseil | - |
5AM Venture Management LLC
 5AM Venture Management LLC Investment ManagersFinance 5AM Ventures invests in companies located in the US with an investment size ranging from $20 to $30 million. The firm targets companies operating in the fields of life sciences. It provides financing for early stage and corporate spin-out capital requirements and also makes co-investments. | Consultant / Advisor | 01/01/2020 |
Ensoma, Inc.
 Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Président | 01/03/2020 |
Kyowa Kirin, Inc.
 Kyowa Kirin, Inc. Pharmaceuticals: OtherHealth Technology Kyowa Kirin, Inc. is a specialty pharmaceutical company dedicated to developing specialty medicines primarily for rare, serious, and underserved diseases. The company is based in Bedminster, NJ. The company focuses on therapeutic areas including bone and mineral diseases, hematologic malignancies and refractory hematologic diseases, nephrology, oncology, immunology, allergy, and neurology. Kyowa Kirin advances modalities such as next-generation antibody therapeutics, hematopoietic stem cell gene therapies, cell therapies, and proprietary antibody technologies. The company operates a network with subsidiaries and research facilities across multiple regions and is expanding manufacturing capacity to support late-stage biologic therapies. Kyowa Kirin emphasizes quality assurance, compliance, and patient safety throughout drug development, clinical trials, manufacturing, and commercialization. The company's clinical research prioritizes diversity and transparency, and they support patient communities and advocacy groups through research and educational initiatives. Partnerships with academic institutions, biotech, pharmaceutical companies, and patient organizations are central to their strategy. The company's portfolio includes medicines such as Crysvita, Poteligeo, Nourianz, and Komzifti, supported by patient assistance programs and expanded access policies. | Directeur/Membre du Conseil | 01/09/2021 |
Anciens postes connus de Paula Soteropoulos
| Sociétés | Poste | Fin |
|---|---|---|
| UNIQURE N.V. | Directeur/Membre du Conseil | 18/06/2024 |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Paula Soteropoulos
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
89
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Tufts University
 Tufts University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
5AM Venture Management LLC
5AM Venture Management LLC Investment ManagersFinance 5AM Ventures invests in companies located in the US with an investment size ranging from $20 to $30 million. The firm targets companies operating in the fields of life sciences. It provides financing for early stage and corporate spin-out capital requirements and also makes co-investments. | Finance |
uniQure NV
 uniQure NV BiotechnologyHealth Technology Engages in the discovery, development and commercialization of gene therapies products | Health Technology |
JFYNetworks, Inc
JFYNetworks, Inc Services to the Health IndustryHealth Services Operates as nonprofit organization that provides young people to build skills for college and careers | Health Services |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for cardiometabolic lipid disorders | Health Technology |
Rallybio LLC
Rallybio LLC Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotech company that delivers groundbreaking therapies | Commercial Services |
Moderna, Inc.
 Moderna, Inc. BiotechnologyHealth Technology Researches, develops, manufactures and commercializes mRNA-based respiratory & other virus vaccines, oncology and rare disease therapeutics | Health Technology |
Dianthus Therapeutics, Inc. (Massachusetts)
Dianthus Therapeutics, Inc. (Massachusetts) BiotechnologyHealth Technology Develops therapies for severe autoimmune diseases | Health Technology |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Commercial Services |
Kyowa Kirin, Inc.
Kyowa Kirin, Inc. Pharmaceuticals: OtherHealth Technology Kyowa Kirin, Inc. is a specialty pharmaceutical company dedicated to developing specialty medicines primarily for rare, serious, and underserved diseases. The company is based in Bedminster, NJ. The company focuses on therapeutic areas including bone and mineral diseases, hematologic malignancies and refractory hematologic diseases, nephrology, oncology, immunology, allergy, and neurology. Kyowa Kirin advances modalities such as next-generation antibody therapeutics, hematopoietic stem cell gene therapies, cell therapies, and proprietary antibody technologies. The company operates a network with subsidiaries and research facilities across multiple regions and is expanding manufacturing capacity to support late-stage biologic therapies. Kyowa Kirin emphasizes quality assurance, compliance, and patient safety throughout drug development, clinical trials, manufacturing, and commercialization. The company's clinical research prioritizes diversity and transparency, and they support patient communities and advocacy groups through research and educational initiatives. Partnerships with academic institutions, biotech, pharmaceutical companies, and patient organizations are central to their strategy. The company's portfolio includes medicines such as Crysvita, Poteligeo, Nourianz, and Komzifti, supported by patient assistance programs and expanded access policies. | Health Technology |
Rallybio Corp.
 Rallybio Corp. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that engages in research, development and commercialization of therapies for patients with severe & rare diseases | Health Technology |
Dianthus Therapeutics, Inc.
 Dianthus Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for patients with autoimmune and inflammatory diseases | Health Technology |
